A new translocation, t(1;3) (p36;q21), in myelodysplastic disorders

A new translocation, t(1;3) (p36;q21), in myelodysplastic disorders.

Myelodysplastic Disorders, 5q-Syndrome

The myelodysplastic syndromes (MDSs) are characterized by ineffective erythropoie‐ sis and progressive cytopenia and ultimately affected patients develop acute myeloid leukemia (AML) or die from advanced bone marrow (BM) failure. Myelodysplastic syndrome (MDS) with isolated del (5q) is a common type of MDS with specific pathological and clinical manifestations including refractory anemia. It is...

Myelodysplastic/myeloproliferative disorders.

ppGalNAc-T13: a new molecular marker of bone marrow involvement in neuroblastoma.

BACKGROUND To identify new molecular markers of bone marrow dissemination in human neuroblastoma (NB), we studied the transcriptome profiles of malignant neuroblasts established from the human MYCN-amplified IGR-N-91 model. METHODS This experimental model includes human neuroblastoma cells derived from a subcutaneous stage 4 disease, myocardium (Myoc) and bone marrow (BM) metastatic cells. ...

Translocation (11;16)(q23;p13) acute myelogenous leukemia and myelodysplastic syndrome.

The purpose of this study is to examine the relationship of t(11;16)(q23;p13) to the type of myeloproliferative disorder noted by hematopathology. Previously, t(11;16) has been reported in fewer than 20 patients, all with the diagnosis of therapy-related (secondary) acute myelogenous leukemia (sAML) or myelodysplastic syndrome (MDS). Putative involved genes are the MLL on 11q23 and CBP at 16p13...